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SUMMARY
Among the priority next steps outlined during the first translational epilepsy research workshop in London, United
Kingdom (2012), jointly organized by the American Epilepsy Society (AES) and the International League Against
Epilepsy (ILAE), are the harmonization of research practices used in preclinical studies and the development of infras-
tructure that facilitates multicenter preclinical studies. The AES/ILAE Translational Task Force of the ILAE has been
pursuing initiatives that advance these goals. In this supplement, we present the first reports of the working groups of
the Task Force that aim to improve practices of performing rodent video–electroencephalography (vEEG) studies in
experimental controls, generate systematic reviews of preclinical research data, and develop preclinical common data
elements (CDEs) for epilepsy research in animals.
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HARMONIZATION INPRECLINICAL EPILEPSYRESEARCH
Following the first international translational workshop
on optimizing preclinical epilepsy in London (2012), jointly
organized by the American Epilepsy Society (AES) and the
International League Against Epilepsy (ILAE),1 a number
of priority steps were recognized as important to undertake.
Among these, defining and harmonizing best research prac-
tices and building an infrastructure to facilitate data compar-
isons and sharing for animal studies were thought to be an
important step to accelerate and optimize preclinical epi-
lepsy research. To implement these efforts, the AES and
ILAE appointed the AES/ILAE Translational Task Force
(TF), co-chaired by Jacqueline French (AES), Aristea Gala-
nopoulou (AES), Terence O’Brien (ILAE), and Michele
Simonato (ILAE). The members of the TF were also jointly
appointed by the AES (Amy Brooks-Kayal, Frances Jensen,
and Helen Scharfman) and ILAE (Marco De Curtis, Akio
Ikeda, and Asla Pitk€anen), whereas Solomon (Nico) Moshe
acted as liaison to the executive committee of the ILAE.
The first tasks agreed upon were the harmonization of
rodent video-electroencephalography (vEEG) and electro-
physiologic studies in rodents (TASK1; co-led by Drs. Gala-
nopoulou, De Curtis, and Ikeda), systematic reviews of
animal model data (TASK2; co-led by Drs Simonato,
Brooks-Kayal, and Jensen), creation of preclinical common
data elements for epilepsy research (TASK3; co-led by Drs.
Scharfman, French, and Pitk€anen), and development of
infrastructure for multicenter preclinical studies (TASK4;
co-led by Drs. O’Brien, Ikeda, and Moshe). Following an
open call for volunteers, each TASK formed working
groups (WGs). The first reports of their work appear in this
supplement.
The TASK1-WGs address the technological, method-
ological aspects, and interpretation of electrophysiologic
studies, done in experimental controls. Unlike human EEG
studies, where there is a standardized way of performing the
studies and their interpretation follows widely accepted
standards and norms, EEG studies in rodents are done using
different types and placements of electrodes and different
acquisition and analysis methods, and their interpretation
varies across labs and investigators. In exploratory studies,
the diversity in methods and definitions is often dictated by
the experimental goals of each study. However, in preclini-
cal studies aiming to ultimately deliver a new treatment,
diagnostic tool, or biomarker to the clinics, harmonization
of the procedures followed to perform or interpret EEG or
in vitro electrophysiologic studies is essential to allow
across study comparisons and cross-validation, minimize
the failures to replicate, and effectively translate the find-
ings to humans, when tested in the clinics. Currently, there
is no organized method of determining a normal back-
ground in rodent EEG studies, no uniform agreement on
what is an electrographic seizure, and no system of classify-
ing seizures or other EEG and electrophysiologic abnormal-
ities in rodents. As a first step, the goal of each of the first
TASK1-WGs was to evaluate and propose methodologic
standards for performing and interpreting electrophysio-
logic studies in rodents used as experimental controls. The
description, definition, terminology, and classification of
the abnormal patterns will be done in the future. Early dis-
cussions among the TASK1-WG members agreed that the
term “normal” is difficult to define in rodents because there
is no prior comprehensive evaluation for neurologic or other
medical disorders, and these animals are exposed to inva-
sive surgeries to place EEG electrodes. As a result, these
first TF reports utilize the term “controls” to denote animals
that have not had exposure to the specific experimental
interventions or settings tested in the respective studies, and
to prompt the investigators to handle and evaluate these con-
trols with the same protocols as the animals allocated to the
other experimental groups. In this supplement, the follow-
ing TASK1 reports are included. The TASK1-WG1 group
reports on best practices pertaining to studies using surface
or epi-/subdural EEG in adult rodent controls.2 The
TASK1-WG3 group addresses the methodologies and inter-
pretation of depth electrophysiologic in studies in vivo in
adult rodent controls,3 whereas the TASK1-WG4 group
focuses on in vitro electrophysiologic studies.4 The
TASK1-WG5 group proposes standards for data acquisition
and analysis for the electrophysiologic recordings.5 Among
the future goals of the TF will be to propose an agreement
on terminology and classification of abnormal vEEG and
electrophysiologic patterns and behaviors, similar to the
classification systems that exist for humans.
The goal of the TASK2 group is to organize systematic
reviews on various topics important for the preclinical epi-
lepsy research studies. This is an effort done through a col-
laboration with CAMARADES (Collaborative Approach to
Meta-Analysis and Review of Animal Data from Experi-
mental Studies) (http://www.dcn.ed.ac.uk/camarades/defa
ult.htm). Electronic citation repositories allow access to
large amounts of articles that cannot be examined by a sin-
gle individual. Moreover, the statistical power of single
basic and preclinical studies is often insufficient to draw
solid conclusions. One approach to address these problems
(well established in clinical research) is the use of system-
atic reviews of the literature and meta-analysis of the data.
The idea of TASK2 is to apply these techniques to preclini-
cal epilepsy studies. There are of course many topics in pre-
clinical epilepsy research that are worthy of systematic
reviews and meta-analysis. The first selected topic was the
identification and characterization of outcome measures
used in animal models of epilepsy.6 This broad analysis is
expected to provide evidence to inform attempts to improve
the currently available models of chronic epilepsy. Future
goals will be to analyze the effects in epilepsy models of
U.S. Food and Drug Administration (FDA)– and European
Medicines Agency (EMA)–approved drugs, using the same
approach. The TASK2 report outlines the objectives, search
strategy, selection criteria, and methods for the statistical
analyses used in this project.
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It is widely believed that harmonization of research
methodology and reporting will speed the evaluation of
translational therapies. Without methodology to allow labs
to perform experiments in similar fashion, or indeed without
availability of reporting mechanisms to determine whether
there were important differences in execution, it is very dif-
ficult to accurately interpret results. Following the experi-
ence of the clinical common data elements (CDEs) (https://
www.commondataelements.ninds.nih.gov/default.aspx#pa
ge=Default) proposed by the National Institute of Neurolog-
ical Disorders and Stroke (NINDS), which have trans-
formed the way clinical trials are being performed and
reported, the TASK3 group, in collaboration with the
NINDS (Drs Brandy Fureman and Vicky Whittemore),
formed several WGs tasked with the creation of preclinical
CDEs and case report forms (CRFs) to be used in animal
studies. These include core CDEs/CRFs or CDEs/CRFs for
assessing behavior, physiologic measures and outcomes,
vEEG studies, or for performing pharmacologic studies in
rodents. The TASK3 report7 presents an overview of the
purpose and utility of these CDEs/CRFs in optimizing data
collection and facilitating collaborative studies and data
sharing. It is also an introduction to the future detailed
reports of the TASK3-WGs, which will present these epi-
lepsy CDEs/CRFs.
These first reports present the first steps of the ongoing
translational initiatives, with the hope that these will be use-
ful in facilitating the harmonization of preclinical studies in
epilepsy research. This will be essential for the successful
implementation of large multicenter preclinical trials, which
aim to provide higher level preclinical evidence to “de-risk”
clinical trials, in particular for potential antiepileptogenic/
disease therapies. The authors welcome feedback from the
community, as it will be essential to finetune and improve
the current and future products of our TF.
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